Back to Search
JASON WESTIN, M.D.
M.D.
Medical Oncology Physician
NPI: 1972615102IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
M4650(TX)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
M4650(TX)
Education
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
Class of 2002
Research & Publications (20)
Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes.
PMID 19437344·Scand J Gastroenterol·2009
4-observational
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
PMID 19673884·Br J Haematol·2009
6-review
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
PMID 18414650·Int J Med Sci·2008
3-trial
Multiplex real-time PCR for detection of respiratory tract infections.
PMID 18093871·J Clin Virol·2008
8-other
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
PMID 18938750·Scand J Gastroenterol·2008
8-other
Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
PMID 18351338·Ann Hematol·2008
8-other
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
PMID 18094721·Leukemia·2008
6-review
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
PMID 18666232·Hepatology·2008
8-other
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.
PMID 18454508·Hepatology·2008
3-trial
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
PMID 17973267·Cancer·2008
4-observational
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
PMID 18268097·Blood·2008
4-observational
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
PMID 17464982·Hepatology·2007
8-other
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
PMID 17581934·J Clin Microbiol·2007
8-other
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
PMID 17212641·J Viral Hepat·2007
3-trial
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
PMID 17187414·Hepatology·2007
8-other
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
PMID 17662258·Biol Psychiatry·2007
7-preclinical
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
PMID 16956822·Haematologica·2006
3-trial
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
PMID 16960776·J Infect Dis·2006
3-trial
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
PMID 16971529·J Neurosci·2006
7-preclinical
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
PMID 17133471·Hepatology·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 1400 Holcombe Blvd, Unit 0429
Houston, TX 77030 - Phone
- (713) 792-3750
Quick Facts
- NPI
- 1972615102
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 24
- Publications
- 20
Are you this provider?
Claim Your Profile